SEC fundamentals

Cyclerion Therapeutics, Inc. (KRSA)

as filed in 10-Q FY2026, period ended Sep 30, 2026 · updated Nov 8, 2026
Total Assets
$462.1M
Stockholders' Equity
$391.6M
Cash & Equivalents
$456.2M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Sep 30, 2026 · View filings on EDGAR ↗

Quarter-end price

Derived from SEC filings · not a live quote · USD per share

Dec 31, 2025
$1.27
From 19 filers
Mar 31, 2026
$1.55
From 17 filers
Jun 30, 2026
$3.39
From 22 filers
Sep 30, 2026
$30.83
As reported · as of Sep 28, 2026

30 quarter-ends on file; the newest 4 shown. Each price is as of its date, from the filings that reported it, and is never adjusted; the full series with each price's sources is in the docs.

In its 10-Q for the period ended Sep 30, 2026, Cyclerion Therapeutics, Inc. reported net income of -$46.4M and total assets of $462.1M. Every figure below is taken directly from Cyclerion Therapeutics, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2019–FY2025 · as reported

$4.5M-$59.3M-$123.0M
FY2019FY2021FY2023FY2025
Revenue$2.1MNet income-$3.5M
FY2019 revenue
$4.5M
FY2025 revenue
$2.1M

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$2.1M-$3.5M
FY2024$2.0M-$3.1M
FY2023$0-$5.3M
FY2022$297,000-$44.1M
FY2021$3.9M-$51.6M
FY2020$2.3M-$77.8M
FY2019$4.5M-$123.0M
FY2018—-$115.3M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
10-QNov 5, 2026on EDGAR ↗
8-KNov 5, 2026on EDGAR ↗
DEF 14AOct 15, 2026on EDGAR ↗
8-KSep 11, 2026on EDGAR ↗
8-KAug 27, 2026on EDGAR ↗
8-KAug 25, 2026on EDGAR ↗
10-QAug 4, 2026on EDGAR ↗
10-QMay 12, 2026on EDGAR ↗
10-K/AApr 30, 2026on EDGAR ↗
8-KApr 1, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Sep 30, 2026 · 10-Q

Total Assets$462.1Msource ↗
Stockholders’ Equity$391.6Msource ↗
Cash & Equivalents$456.2Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Sep 30, 2026

Revenue—source ↗
Net Income-$46.4Msource ↗
Operating Income-$48,274source ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$42,139source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Sep 30, 2026

EPS (diluted)$-3.19source ↗
EPS (basic)$-3.19source ↗
Shares Outstanding45.5Msource ↗
Cash from Operations-$46.8Msource ↗
Cash from Financing$351.1Msource ↗
Cash from Investing-$231,000source ↗

Insider activity

Form 4 open-market activity, last 180 days

No open-market Form 4 transactions filed in the last 180 days.

Restatement history

Point-in-time

3 of 170 annual fact-keys were materially restated between filings: what Cyclerion Therapeutics, Inc. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches KRSA’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Starter extends the ratios to 20 quarters and adds the Piotroski F-score and accruals quality score; Analyst extends the trajectory to up to 20 years. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Starter removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/KRSA

MCP tool: get_sec_fundamentals ticker=KRSA

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/KRSA/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=KRSA as_of=YYYY-MM-DD

Quarter-end prices derived from SEC filings, with their sources and splits
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/prices/KRSA/history?frequency=quarter

MCP tool: get_sec_price_history ticker=KRSA frequency=quarter

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/KRSA/history

MCP tool: get_fundamentals_history ticker=KRSA

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/KRSA

MCP tool: get_financial_health ticker=KRSA

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.